Healthpeak Properties Raises 2026 Earnings Guidance Following Completion of the Janus Living IPO, Accretive Capital Allocation, and Strong First Quarter 2026 Results
FIRST QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
-
Net income of
$0.28 per share, Nareit FFO of$0.42 per share, and FFO as Adjusted of$0.45 per share -
In
March 2026 , (NYSE: JAN) ("Janus Living , Inc.Janus Living ") completed its initial public offering ("IPO") at the high-end of the valuation range, generating approximately$880 million of net proceeds in an oversubscribed and upsized offering, to pursue accretive acquisition and investment opportunities-
As
Janus Living's largest shareholder, Healthpeak's earnings growth will benefit from the favorable senior housing supply-demand fundamentals andJanus Living's accretive external growth opportunities $714 million of previously disclosed Healthpeak senior housing acquisitions contributed toJanus Living as part of the formation transactionsJanus Living reported it is under contract on an additional$400 million of senior housing acquisitions-
As of
May 4, 2026 ,Janus Living had a market capitalization of$6.9 billion , of which Healthpeak owns 81.6%
-
As
-
Janus Living reported post-IPO net loss of$(0.05) per share, first quarter net income of$0.13 per share and first quarter FFO as Adjusted of$0.23 per share- Year-over-year consolidated revenue and Adjusted EBITDAre growth of 35% and 42%, respectively
-
First quarter
Outpatient Medical and Lab new and renewal lease executions totaled 1.2 million square feet:-
Outpatient Medical new lease executions totaled 195,000 square feet and renewal lease executions totaled 868,000 square feet, with +5.4% cash releasing spreads on renewals
-
Subsequent to the first quarter, and through
May 4, 2026 , executed 1 million square feet of Outpatient Medical leases and signed letters of intent ("LOI")
-
Subsequent to the first quarter, and through
-
Lab new lease executions totaled 129,000 square feet and renewal lease executions totaled 12,000 square feet and +3.5% cash releasing spreads on renewals
-
Subsequent to the first quarter, and through
May 4, 2026 , executed 354,000 square feet of Lab leases and signed LOIs
-
Subsequent to the first quarter, and through
-
Outpatient Medical new lease executions totaled 195,000 square feet and renewal lease executions totaled 868,000 square feet, with +5.4% cash releasing spreads on renewals
- Lab total occupancy increased sequentially and is expected to increase through year-end 2026
-
Generated
$267 million of proceeds from recapitalizations, dispositions, and loan repayments-
In
March 2026 , closed on the recapitalization and sale of an 80% joint venture interest in a 100% occupied, six-property outpatient medical portfolio to affiliates ofBlackstone at a gross valuation of$212 million , generating proceeds of approximately$170 million
-
In
-
In
April 2026 , repurchased 5.9 million common shares at a weighted average share price of$16.81 for approximately$100 million -
Net Debt to Adjusted EBITDAre was 5.4x for the quarter ended
March 31, 2026 -
Recent corporate impact and sustainability achievements include:
-
Awarded LEED
Silver Core & Shell for Medical City McKinney, an outpatient medical development located in suburbanDallas - Named a member of the Dow Jones Best-in-Class (DJBIC) North America Index for the 13th consecutive year
- Named a constituent in the S&P Global Sustainability Yearbook for the 11th consecutive year
-
Awarded LEED
To learn more about Healthpeak's commitment to responsible business and view our Corporate Impact Report, please visit www.healthpeak.com/corporate-impact.
FIRST QUARTER COMPARISON
|
|
Three Months Ended
|
|
Three Months Ended
|
||||||||
|
(in thousands, except per share amounts) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
||||
|
Diluted Net income (loss) applicable to common shares |
$ |
193,484 |
|
$ |
0.28 |
|
$ |
42,364 |
|
$ |
0.06 |
|
Diluted Nareit FFO applicable to common shares |
|
301,519 |
|
|
0.42 |
|
|
323,279 |
|
|
0.45 |
|
Diluted FFO as Adjusted applicable to common shares |
|
316,853 |
|
|
0.45 |
|
|
329,713 |
|
|
0.46 |
SAME-STORE ("SS") OPERATING SUMMARY
The table below outlines the year-over-year three-month total SS Cash (Adjusted) NOI growth.
|
Year-Over-Year Total Same-Store Adjusted NOI Growth |
||||
|
|
Three Month |
|||
|
|
SS Growth % |
% of SS |
||
|
Outpatient Medical |
2.4 |
% |
55.7 |
% |
|
Lab |
(7.2 |
%) |
33.6 |
% |
|
|
13.8 |
% |
10.7 |
% |
|
Total SS Cash (Adjusted) NOI |
0.0 |
% |
100.0 |
% |
Nareit FFO, FFO as Adjusted, Total Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts. See "
DIVIDEND
On
|
Record Date |
Payment Date |
Amount |
|
|
|
|
|
|
|
|
|
|
|
|
JANUS LIVING INITIAL PUBLIC OFFERING
In
As of the IPO, Healthpeak owned approximately 214.7 million shares of common stock and operating partnership common units in
On
Janus Living’s operations are consolidated into Healthpeak’s financial statements, with the approximately 18.4% not owned by Healthpeak reported as noncontrolling interest.
SENIOR HOUSING ACQUISITIONS
During the first quarter 2026, Healthpeak closed on senior housing acquisitions totaling
A summary of the acquisitions is as follows:
-
Our joint venture partner's 46.5% interest in a 19-community portfolio for
$314 million -
Three communities in the Orlando MSA for
$119 million -
Two communities in the Atlanta MSA for
$240 million -
One community in the Seattle MSA for
$41 million
SHARE REPURCHASE ACTIVITY
In
As of
OUTPATIENT MEDICAL JOINT VENTURE RECAPITALIZATION
In
Under the terms of the joint venture,
DISPOSITIONS
During the first quarter 2026, Healthpeak closed on approximately
BALANCE SHEET
As previously disclosed, in
2026 GUIDANCE
We are updating the following guidance ranges for full year 2026:
-
Diluted earnings per common share from
$0.34 –$0.38 to$0.46 –$0.50 -
Diluted Nareit FFO per share from
$1.70 –$1.74 to$1.68 –$1.72 -
Diluted FFO as Adjusted per share from
$1.70 –$1.74 to$1.71 –$1.75
We are reaffirming full year 2026 Total Same-Store Cash (Adjusted) NOI growth in the range of (1.0%) – 1.0%
These estimates are based on our current view of existing market conditions, transaction timing, and other assumptions for the year ending
CONFERENCE CALL INFORMATION
Healthpeak has scheduled a conference call and webcast for
- Healthpeak’s website: https://ir.healthpeak.com/news-events
- Webcast: https://events.q4inc.com/attendee/885401057. Joining via webcast is recommended for those who will not be asking questions.
- Telephone: The participant dial-in number is (833) 461-5787. The international dial-in is (585) 542-9983. The conference ID number is 885401057.
A webcast replay will be available on Healthpeak’s website through
ABOUT HEALTHPEAK
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to the proposed Janus Living IPO or current, pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release; (ii) the payment of a monthly cash dividend; and (iii) the information presented under the heading "2026 Guidance Information." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: changes to regulatory, funding, staffing, trade, and other policies and actions by the
Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
|
Consolidated Balance Sheets In thousands, except share and per share data |
|||||||
|
|
|
|
|
||||
|
Assets |
|
|
|
||||
|
Real estate: |
|
|
|
||||
|
Buildings and improvements |
$ |
17,168,415 |
|
|
$ |
16,593,535 |
|
|
Development costs and construction in progress |
|
1,056,909 |
|
|
|
1,010,657 |
|
|
Land and improvements |
|
3,221,127 |
|
|
|
3,007,346 |
|
|
Accumulated depreciation |
|
(4,609,647 |
) |
|
|
(4,512,443 |
) |
|
Net real estate |
|
16,836,804 |
|
|
|
16,099,095 |
|
|
Loans receivable, net of reserves of |
|
631,648 |
|
|
|
606,020 |
|
|
Investments in unconsolidated joint ventures |
|
530,354 |
|
|
|
802,601 |
|
|
Accounts receivable, net of allowance of |
|
91,467 |
|
|
|
78,327 |
|
|
Cash and cash equivalents |
|
1,170,992 |
|
|
|
467,457 |
|
|
Restricted cash |
|
94,917 |
|
|
|
70,245 |
|
|
Intangible assets |
|
758,495 |
|
|
|
654,516 |
|
|
Assets held for sale |
|
45,667 |
|
|
|
80,621 |
|
|
Right-of-use asset |
|
395,929 |
|
|
|
412,198 |
|
|
Deferred tax assets |
|
120,310 |
|
|
|
111,248 |
|
|
|
|
68,529 |
|
|
|
68,529 |
|
|
Other assets |
|
871,113 |
|
|
|
885,161 |
|
|
Total assets |
$ |
21,616,225 |
|
|
$ |
20,336,018 |
|
|
|
|
|
|
||||
|
Liabilities and Equity |
|
|
|
||||
|
Bank line of credit and commercial paper |
$ |
1,751,409 |
|
|
$ |
1,078,850 |
|
|
Term loans |
|
1,645,731 |
|
|
|
1,647,113 |
|
|
Senior unsecured notes |
|
6,779,171 |
|
|
|
6,772,722 |
|
|
Mortgage debt |
|
246,461 |
|
|
|
349,209 |
|
|
Intangible liabilities |
|
164,360 |
|
|
|
173,697 |
|
|
Liabilities related to assets held for sale |
|
545 |
|
|
|
11,900 |
|
|
Lease liability |
|
290,089 |
|
|
|
296,260 |
|
|
Accounts payable, accrued liabilities, and other liabilities |
|
671,245 |
|
|
|
718,509 |
|
|
Deferred revenue |
|
1,007,201 |
|
|
|
985,307 |
|
|
Total liabilities |
|
12,556,212 |
|
|
|
12,033,567 |
|
|
|
|
|
|
||||
|
Commitments and contingencies |
|
|
|
||||
|
|
|
|
|
||||
|
Redeemable noncontrolling interests |
|
27,214 |
|
|
|
159,581 |
|
|
|
|
|
|
||||
|
Common stock, |
|
695,263 |
|
|
|
695,037 |
|
|
Additional paid-in capital |
|
13,102,990 |
|
|
|
12,767,914 |
|
|
Cumulative dividends in excess of earnings |
|
(5,971,501 |
) |
|
|
(5,952,920 |
) |
|
Accumulated other comprehensive income (loss) |
|
(464 |
) |
|
|
(9,937 |
) |
|
Total stockholders’ equity |
|
7,826,288 |
|
|
|
7,500,094 |
|
|
|
|
|
|
||||
|
Public investors of |
|
560,426 |
|
|
|
— |
|
|
Joint venture partners |
|
294,297 |
|
|
|
295,455 |
|
|
Non-managing member unitholders |
|
351,788 |
|
|
|
347,321 |
|
|
Total noncontrolling interests |
|
1,206,511 |
|
|
|
642,776 |
|
|
|
|
|
|
||||
|
Total equity |
|
9,032,799 |
|
|
|
8,142,870 |
|
|
|
|
|
|
||||
|
Total liabilities and equity |
$ |
21,616,225 |
|
|
$ |
20,336,018 |
|
|
Consolidated Statements of Operations In thousands, except per share data |
|||||||
|
|
Three Months Ended
|
||||||
|
|
|
2026 |
|
|
|
2025 |
|
|
Revenues: |
|
||||||
|
Rental and related revenues |
$ |
538,436 |
|
|
$ |
538,141 |
|
|
Resident fees and services |
|
200,345 |
|
|
|
148,927 |
|
|
Interest income and other |
|
14,171 |
|
|
|
15,821 |
|
|
Total revenues |
|
752,952 |
|
|
|
702,889 |
|
|
|
|
|
|
||||
|
Costs and expenses: |
|
|
|
||||
|
Operating |
|
323,861 |
|
|
|
273,143 |
|
|
Depreciation and amortization |
|
289,734 |
|
|
|
268,546 |
|
|
Interest expense |
|
87,292 |
|
|
|
72,693 |
|
|
General and administrative |
|
24,591 |
|
|
|
26,118 |
|
|
Transaction costs |
|
24,149 |
|
|
|
5,534 |
|
|
Impairments and loan loss reserves (recoveries), net |
|
(2,275 |
) |
|
|
(3,562 |
) |
|
Total costs and expenses |
|
747,352 |
|
|
|
642,472 |
|
|
Other income (expense): |
|
|
|
||||
|
Gain (loss) on sales of real estate, net |
|
50,669 |
|
|
|
— |
|
|
Gain (loss) on debt extinguishments |
|
(403 |
) |
|
|
— |
|
|
Other income (expense), net |
|
139,779 |
|
|
|
(6,126 |
) |
|
Total other income (expense), net |
|
190,045 |
|
|
|
(6,126 |
) |
|
|
|
|
|
||||
|
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |
|
195,645 |
|
|
|
54,291 |
|
|
Income tax benefit (expense) |
|
(254 |
) |
|
|
(2,080 |
) |
|
Equity income (loss) from unconsolidated joint ventures |
|
4,265 |
|
|
|
(2,147 |
) |
|
Net income (loss) |
|
199,656 |
|
|
|
50,064 |
|
|
Noncontrolling interests’ share in earnings |
|
(6,023 |
) |
|
|
(7,236 |
) |
|
Net income (loss) attributable to |
|
193,633 |
|
|
|
42,828 |
|
|
Participating securities’ share in earnings |
|
(149 |
) |
|
|
(464 |
) |
|
Net income (loss) applicable to common shares |
$ |
193,484 |
|
|
$ |
42,364 |
|
|
|
|
|
|
||||
|
Earnings per common share: |
|
|
|
||||
|
Basic |
$ |
0.28 |
|
|
$ |
0.06 |
|
|
Diluted |
$ |
0.28 |
|
|
$ |
0.06 |
|
|
Weighted average shares outstanding: |
|
|
|
||||
|
Basic |
|
695,161 |
|
|
|
699,067 |
|
|
Diluted |
|
695,168 |
|
|
|
699,118 |
|
|
Funds From Operations In thousands, except per share data |
|||||||
|
|
Three Months Ended
|
||||||
|
|
|
2026 |
|
|
|
2025 |
|
|
|
|
||||||
|
Net income (loss) applicable to common shares |
$ |
193,484 |
|
|
$ |
42,364 |
|
|
Real estate related depreciation and amortization |
|
289,734 |
|
|
|
268,546 |
|
|
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures |
|
7,212 |
|
|
|
12,200 |
|
|
Noncontrolling interests’ share of real estate related depreciation and amortization |
|
(4,702 |
) |
|
|
(4,454 |
) |
|
Loss (gain) on sales of depreciable real estate, net |
|
(50,669 |
) |
|
|
— |
|
|
Loss (gain) upon change of control, net(1) |
|
(138,117 |
) |
|
|
— |
|
|
Taxes associated with real estate dispositions |
|
58 |
|
|
|
— |
|
|
Nareit FFO applicable to common shares |
|
297,000 |
|
|
|
318,656 |
|
|
Distributions on dilutive convertible units and other |
|
4,519 |
|
|
|
4,623 |
|
|
Diluted Nareit FFO applicable to common shares |
$ |
301,519 |
|
|
$ |
323,279 |
|
|
Diluted Nareit FFO per common share |
$ |
0.42 |
|
|
$ |
0.45 |
|
|
Weighted average shares outstanding - Diluted Nareit FFO |
|
709,457 |
|
|
|
714,174 |
|
|
Impact of adjustments to Nareit FFO: |
|
|
|
||||
|
Transaction, merger, and restructuring-related costs(2) |
$ |
20,568 |
|
|
$ |
5,534 |
|
|
Other impairments (recoveries) and other losses (gains), net(3) |
|
(2,275 |
) |
|
|
(3,320 |
) |
|
Loss (gain) on debt extinguishments |
|
302 |
|
|
|
— |
|
|
Casualty-related charges (recoveries), net(4) |
|
(190 |
) |
|
|
4,226 |
|
|
Recognition (reversal) of valuation allowance on deferred tax assets(5) |
|
(3,058 |
) |
|
|
— |
|
|
Total adjustments |
|
15,347 |
|
|
|
6,440 |
|
|
FFO as Adjusted applicable to common shares |
|
312,347 |
|
|
|
325,096 |
|
|
Distributions on dilutive convertible units and other |
|
4,506 |
|
|
|
4,617 |
|
|
Diluted FFO as Adjusted applicable to common shares |
$ |
316,853 |
|
|
$ |
329,713 |
|
|
Diluted FFO as Adjusted per common share |
$ |
0.45 |
|
|
$ |
0.46 |
|
|
Weighted average shares outstanding - Diluted FFO as Adjusted |
|
709,457 |
|
|
|
714,174 |
|
|
|
|
|
|
||||
|
Other operating data: |
|
|
|
||||
|
Amortization of deferred financing costs and debt discounts (premiums) |
$ |
8,363 |
|
|
$ |
7,852 |
|
|
Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization |
|
7,756 |
|
|
|
4,696 |
|
|
Stock-based compensation amortization expense |
|
4,502 |
|
|
|
4,627 |
|
|
Deferred income taxes |
|
3,053 |
|
|
|
2,570 |
|
|
AFFO capital expenditures |
|
(23,956 |
) |
|
|
(23,136 |
) |
|
Straight-line rents |
|
(10,905 |
) |
|
|
(11,153 |
) |
|
Amortization of above (below) market lease intangibles, net |
|
(6,597 |
) |
|
|
(10,212 |
) |
|
Other items(6) |
|
(2,606 |
) |
|
|
1,451 |
|
|
_______________________________________ |
|
|
(1) |
The three months ended |
|
(2) |
The three months ended |
|
(3) |
The three months ended |
|
(4) |
Casualty-related charges (recoveries), net are recognized in other income (expense), net, equity income (loss) from unconsolidated joint ventures, and noncontrolling interests’ share in earnings in the Consolidated Statements of Operations. |
|
(5) |
The three months ended |
|
(6) |
Primarily includes: (i) amortization of deferred revenue, (ii) noncontrolling interests’ share of senior housing entrance fees in excess (less) than the related GAAP amortization, and (iii) our proportionate share of AFFO capital expenditures and straight-line rents from unconsolidated joint ventures. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260505342810/en/
Senior Vice President – Finance and Investor Relations
720-428-5400
Source: